Imaging scans to study myelofibrosis, a bone marrow disease
Uses PET imaging scans to look for scarring in adults with myelofibrosis.
Plain-language title generated from the registry record
Registry title: 18F-FAPI PET/MRI Imaging in Myelofibrosis: a Prospective Observational Study.
Key facts
- Where
- Hangzhou, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06164561, who can take part
Where in China
- The First Affiliated Hospital Zhejiang University School of MedicineHangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- First Affiliated Hospital of Zhejiang University
- Trial code
- NCT06164561
- Record updated
- 4 February 2026
- Original description
This study intends to use a prospective, observational, self-controlled, multi-center study design to evaluate the feasibility and diagnostic efficacy of 18F-FDG PET/CT and 18F-FAPI PET/MRI imaging for the evaluation of systemic fibrosis in MF patients based on the results of bone marrow pathological biopsy, and to analyze the relationship between imaging results and clinical prognosis.Read full original descriptionShow less
18F-FAPI PET/MRI Imaging in the Diagnosis and Monitoring of Therapeutic Effect of Myelofibrosis: a Prospective Observational Study.
This study intends to use a prospective, observational, self-controlled, multi-center study design to evaluate the feasibility and diagnostic efficacy of 18F-FDG PET/CT and 18F-FAPI PET/MRI imaging for the evaluation of systemic fibrosis in MF patients based on the results of bone marrow pathological biopsy, and to analyze the relationship between imaging results and clinical prognosis.
Inclusion: Patients with primary myelofibrosis or myelofibrosis secondary to myeloid tumors were diagnosed according to the diagnostic criteria of who 2022; Stable vital signs, ECOG score ≥ 2 points, tolerate and cooperate to complete 18F-FDG PET/CT and 18F-FAPI PET/MRI examination; The interval between imaging ,hematologic, cytogenetic and pathology was < 2 weeks; Willing to accept 18F-FDG PET/CT and 18F-FAPI PET/MRI , sign the informed consent.
Exclusion: Current infection was present within 1 week before PET examination; Have received glucocorticoid therapy within 2 weeks before PET imaging examination; Using granulocyte colony-stimulating factor (G-CSF) within 4 weeks prior to PET imaging; Other malignancies, autoimmune diseases, or chronic active infections were diagnosed within 1 year before the diagnosis of myelofibrosis; Inability or unwillingness to provide informed consent; Pregnant or lactation; Unable to follow protocol to complete follow-up.